Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIkido Pharma SPEX

Healthcare Biotechnology
AIkido Pharma Inc is a United States-based biotechnology company. The company is engaged in the development of small-molecule anti-cancer therapeutics. The company's drug portfolio includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).

Recent & Breaking News (NDAQ:SPEX)

AIkido Pharma Continues Share Repurchase Program

PR Newswire October 3, 2022

AIkido Provides Update on Use of Machine Learning in Drug Development Program

PR Newswire August 6, 2021

Notice of Allowance Issued for Central Nervous System Peptide Technology

PR Newswire July 27, 2021

AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland

PR Newswire July 16, 2021

AIkido Pharma to Attend the Alzheimer's Association International Conference

PR Newswire July 13, 2021

AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease

PR Newswire June 23, 2021

AIkido Pharma Announces Positive Phase 1 Data Presented at ASCO on 225Ac-J591

PR Newswire June 4, 2021

AIkido Pharma Announces Phase 1 Data To Be Presented at the American Society of Clinical Oncology ("ASCO") Annual Meeting

PR Newswire May 20, 2021

AIKI Featured as Stock to Watch Ahead of Significant Key Milestones

Newsfile May 19, 2021

AIkido Pharma Inc.: Invitation to the Q2 Virtual Investor Summit

Newsfile May 13, 2021

AIKI's Near Term Catalyst Approaching this Quarter with Strong Cash Balance Sheet for Strategic Initiatives

Newsfile May 13, 2021

AIkido Pharma Inc. to Present at the Benzinga Global Small Cap Conference, the Investor Summit Group's Conference, and the LD Micro Invitational Conference

PR Newswire May 12, 2021

AIkido Pharma Inc. Announces First Quarter 2021 Results and Provides Corporate Update

PR Newswire May 11, 2021

AIkido Pharma Inc. Announces Participation in the Benzinga Global Small Cap Conference

Newsfile May 6, 2021

AIkido Pharma Announces Dr. Rachel Yehuda's Appearance at SXSW

PR Newswire April 27, 2021

AIkido Pharma Announces Inventor and Scientist Dr. Matthew Frieman Joins Scientific Advisory Board

PR Newswire April 26, 2021

AIkido Pharma Announces Withdrawal of S-1 Registration Statement

PR Newswire April 22, 2021

AIkido Pharma Notes Advancement in Radiopharmaceutical Research

PR Newswire April 16, 2021

AIkido Granted Sublicense to Technology for Targeted Psilocybin Treatment of Neuro-Inflamed Tissue in Cancer Patients

PR Newswire April 7, 2021

AIkido Pharma Provides Business Update

PR Newswire April 5, 2021